43 related articles for article (PubMed ID: 2752132)
41. Risk classification as the basis for clinical staging of diffuse large-cell lymphoma derived from 10-year survival data.
Velasquez WS; Jagannath S; Tucker SL; Fuller LM; North LB; Redman JR; Swan F; Hagemeister FB; McLaughlin P; Cabanillas F
Blood; 1989 Aug; 74(2):551-7. PubMed ID: 2752132
[TBL] [Abstract][Full Text] [Related]
42. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
43. [CHOP-Bleo therapy in high-malignancy non-Hodgkin lymphoma].
Schneider T; Molnár Z; Várady E; Ringwald G; Fleischmann T
Orv Hetil; 1994 Dec; 135(50):2759-63. PubMed ID: 7530823
[TBL] [Abstract][Full Text] [Related]
[Previous] [New Search]
